Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Ma, Xiaomeng ^a   Jiang, Ying ^a   Wu, Aimin ^a   Chen, Xiaohong ^a   Pi, Rongbiao ^a   Liu, Mei ^a   Liu, Yingying ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; GELATINASE A; GELATINASE B; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEINASE INHIBITOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; ONSET AGE; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; PATHOLOGY; WESTERN BLOTTING;

MUS;

ANIMALS; BERBERINE; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; PROTEASE INHIBITORS;

EID: 78149420304     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013489     Document Type: Article

References (55)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343: 938-952.
2. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, et al. (2003) Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422: 688-694.
3. Keegan BM, Noseworthy JH (2002) Multiple sclerosis. Annu Rev Med 53: 285-302.
4. Hartung HP, Kieseier BC (2000) The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 107: 140-147.
5. Yong VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2: 502-511.
6. Ikram M (1975) A review on the chemical and pharmacological aspects of genus Berberis. Planta Med 28: 353-358.
7. Kuo CL, Chi CW, Liu TY (2004) The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203: 127-137.
8. Hwang JM, Kuo HC, Tseng TH, Liu JY, Chu CY (2006) Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Arch Toxicol 80: 62-73.
9. Nishino H, Kitagawa K, Fujiki H, Iwashima A (1986) Berberine sulfate inhibits tumor-promoting activity of teleocidin in two-stage carcinogenesis on mouse skin. Oncology 43: 131-134.
10. Peng PL, Hsieh YS, Wang CJ, Hsu JL, Chou FP (2006) Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol Appl Pharmacol 214: 8-15.
11. Tang J, Feng YB, Tsao S, Wang N, Curtain R, et al. (2009) Berberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations. J Ethnopharmacol 126: 5-17.
12. Zhou XQ, Zeng XN, Kong H, Sun XL (2008) Neuroprotective effects of berberine on stroke models in vitro and in vivo. Neurosci Lett 447: 31-36.
13. Chen FL, Yang ZH, Liu Y, Li LX, Liang WC, et al. (2008) Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Endocrine 33: 331-337.
14. Kim S, Kim Y, Kim JE, Cho KH, Chung JH (2008) Berberine inhibits TPAinduced MMP-9 and IL-6 expression in normal human keratinocytes. Phytomedicine 15: 340-347.
15. Ho YT, Yang JS, Li TC, Lin JJ, Lin JG, et al. (2009) Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9. Cancer Lett 279: 155-162.
16. Chen XH, Hu XQ, Zou Y, Pi RP, Liu M, et al. (2009) Combined treatment with minocycline and prednisone attenuates experimental autoimmuneencephalomyelitis in C57 BL/6 mice. J Neuroimmunol 210: 22-29.
17. Racke MK, Quigley L, Cannella B, Raine CS, McFarlin DE, et al. (1994) Superantigen modulation of experimental allergic encephalomyelitis: activation of energy determines outcome. J Immunol 152: 2051-2059.
18. O'Neill EJ, Day MJ, Wraith DC (2006) IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE. J Neuroimmunol 178: 1-8.
19. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, et al. (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106: 1755-1761.
20. Kuerten S, Kostova-Bales DA, Frenzel LP, Tigno JT, Tary-Lehmann M, et al. (2007) MP4-and MOG: 35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum. J Neuroimmunol 189: 31-40.
21. Engelhardt B, Vestweber D, Hallmann R, Schulz M (1997) E- and P-selectin are notinvolved in the recruitment of inflammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis. Blood 90: 4459-4472.
22. Lassmann H, Schwerer B, Kitz K, Egghart M, Bernheimer H (1983) Pathogenetic aspects of demyelinating lesions in chronic relapsing experimental allergic encephalomyelitis: possible interaction of cellular and humoral immune mechanisms. Prog Brain Res 59: 305-315.
23. Weiss N, Miller F, Cazaubon S, Couraud PO (2009) The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 1788: 842-857.
24. De Vries HE, Kuiper J, De Boer AG, Van Berkel TJC, Breimer DD (1997) The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev 49: 143-155.
25. Danel PM, Lam DKC, Pratt OE (1983) Relation between the increase in the diffusional permeability of the blood-central nervous system barrier and other changes during the development of experimental allergic encephalomyelitis in the Lewis rat. J Neurol Sci 60: 367-376.
26. Fabis MJ, Scott GS, Kean RB, Koprowski H, Hooper DC (2007) Loss of bloodbrain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proc Natl Acad Sci USA 104: 5656-5661.
27. Kean RB, Spitsin SV, Mikheeva T, Scott GS, Hooper DC (2000) The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol 165: 6511-6518.
28. Brown KA (2001) Factors modifying the migration of lymphocytes across the blood-brain barrier. Intl Immunopharmacol 1: 2043-2062.
29. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, et al. (2003) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 136: 46-53.
30. Mun-Bryce S, Rosenberg GA (1998) Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol Regulatory Integrative Comp Physiol 274: 1203-1211.
31. Conant K, McArthur JC, Griffin DE, Sjulson L, Wahl LM, et al. (1999) Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol 46: 391-398.
32. Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378: 151-60.
33. Zhao H, Bernardo MM, Osenkowski P, Sohail A, Pei D, et al. (2004) Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation. J Biol Chem 279: 8592-8601.
34. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, et al. (1993) Matrix metalloproteinases: a review. Crit Rev Oral Biol Med4: 197-250.
35. Mandler RN, Dencoff JD, Midani F, Ford CC, Ahmed W, et al. (2001) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. Brain 124: 493-98.
36. Matrisian LM (1990) Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121-125.
37. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, et al. (1996) The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 55: 1194-1204.
38. Huang Z, Wang L, Meng S, Wang Y, Chen T, et al. (2009) Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages. Int J Cardiol Xxx: xxx-xxx.
39. Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8: 205-216.
40. Mirowska D, Wicha W, Czlonkowskic A, Czlonkowska A, Weber F (2004) Increase of matrix metalloproteinase-9 in peripheral blood of multiple sclerosis patients treated with high doses of methylprednisolone. J Neuroimmunol 146: 171-175.
41. Huhtala P, Chow LT, Tryggvason K (1990) Structure of the human type IV collagenase gene. J Biol Chem 265: 11077-11082.
42. Anthony DC, Miller KM, Fearn S, Townsend MJ, Opdenakker G, et al. (1998) Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol 87: 62-72.
43. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, et al. (1997) Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 6: 590-598.
44. Dubois B, Masure S, Hurtenbach U, Paemen L, Heremans H, et al. (1999) Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 104: 1507-1515.
45. Romanic AM, Madri JA (1994) The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol 125: 1165-1178.
46. Esparza J, Kruse M, Lee J, Michaud M, Madri JA (2004) MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J 18: 1682-1691.
47. Xu LH, Liu Y, He XH (2005) Inhibitory Effects of Berberine on the Activation and Cell Cycle Progression of Human Peripheral Lymphocytes. Cellular & Molecular Immunology 2: 295-300.
48. Li H, Miyahara T, Tezuka Y, Tran QL, Seto H, et al. (2003) Effect of berberine on bone mineral density in SAMP6 as a senile osteoporosis model. Biol Pharm Bull 26: 110-111.
49. Pan LR, Tang Q, Fu Q, Hu BR, Xiang JZ, et al. (2005) Roles of nitric oxide in protective effect of berberine in ethanol-induced gastric ulcer mice. Acta Pharmacol Sin 26: 1334-1338.
50. Mitani N, Murakami K, Yamaura T, Ikeda T, Saiki I (2001) Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma. Cancer Lett 165: 35-42.
51. Kozler P, Pokorný J (2003) Altered blood-brain barrier permeability and its effect on the distribution of Evans blue and sodium fluorescein in the rat brain applied by intracarotid injection. Physiol Res 52: 607-614.
52. Guo M, Cox B, Mahale S, Davis W, Carranza A, et al. (2008) Pre-ischemic exercise reduces matrix metalloproteinase-9 expression and ameliorates bloodbrain barrier dysfunction in stroke. Neuroscience 151: 340-351.
53. Leib SL, Leppert D, Clements J, Tauber MG (2000) Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun 68: 615-620.
54. Liu XJ, Han QZH, Sun RP, Li ZHX (2008) Dexamethasone regulation of matrix metalloproteinase expression in experimental pneumococcal meningitis. Brain Res 1207: 237-243.
55. Kolb SA, Lahrtz F, Paul R, Leppert D, Nadal D, et al. (1998) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J Neuroimmunol 84: 143-150.